The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer

• Published in: Cancer communications (London, England) Vol. 41; no. 7; pp. 560 - 575
• Main Authors: Wang, Jing‐Zi, Zhu, Wei, Han, Jie, Yang, Xiao, Zhou, Rui, Lu, Hong‐Cheng, Yu, Hao, Yuan, Wen‐Bo, Li, Peng‐Chao, Tao, Jun, Lu, Qiang, Wei, Ji‐Fu, Yang, Haiwei
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.07.2021; John Wiley and Sons Inc; Wiley
• Subjects: 5‐methylcytidine modification; ALYREF; Antibodies; Bladder cancer; Carcinogenesis - genetics; Carrier Proteins; Cell Line, Tumor; Gene expression; glycolysis; Glycolysis - genetics; HIF‐1α; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit - genetics; Kinases; Membrane Proteins; Nuclear Proteins; Original; PKM2; Plasmids; Polymerase chain reaction; Proteins; RNA-Binding Proteins; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcription Factors; Urinary Bladder Neoplasms - genetics; United States > US; China; 5-methylcytidine modification; HIF-1α; PKM2; ALYREF; bladder cancer; glycolysis

Background As a rate‐limiting enzyme of glycolysis, pyruvate kinase muscle isozyme M2 (PKM2) participates in tumor metabolism and growth. The regulatory network of PKM2 in cancer is complex and has not been fully studied in bladder cancer. The 5‐methylcytidine (m5C) modification in PKM2 mRNA might p...